The case was seen as a test of a more aggressive policy by the agency.
Related Posts
BioMarin to Acquire Amicus Therapeutics for $4.8 Billion — A Strategic Push to Tighten Rare‑Disease Leadership
BioMarin Pharmaceutical has agreed to acquire Amicus Therapeutics in an all‑cash deal valued at approximately $4.8 billion
Philips Bets On AI To See Inside Arteries With SpectraWAVE Buy
Royal Philips (NYSE: PHG), a global leader in medical technology, has agreed to acquire SpectraWAVE, Inc., a Massachusetts-based innovator in **AI-powered intravascular imaging**, to bolster its...
Nippon Life’s Strategic Leap: Pursuing a Medical‑data Platform in a Milestone Buy
Nippon Life Insurance Co. is pursuing an acquisition of a Japanese medical‑data firm, marking what executives describe as a strategic milestone as the insurer shifts from traditional asset...
Japanese Pharmas Expand Cross-Border M&A Footprint in US and EU Amid Domestic Market Stagnation
Japanese pharmaceutical companies are increasingly pursuing mergers and acquisitions (M&A) beyond their domestic borders, targeting strategic assets in the United States and Europe to drive growth...